Approved agents for metastatic breast cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Metastatic breast cancer (MBC) poses significant treatment challenges, especially when resistant to anthracyclines and taxanes.
• Limited therapeutic options and short median survival underscore the need for effective strategies in refractory MBC.

Purpose of the Study:

• To review current treatment options for patients with metastatic breast cancer refractory to anthracyclines and taxanes.
• To highlight factors influencing treatment selection and the ongoing research efforts in this area.

Main Methods:

• Review of US Food and Drug Administration (FDA)-approved agents for refractory MBC.
• Discussion of clinical considerations for treatment decision-making.

Main Results:

• Three agents—capecitabine, ixabepilone, and eribulin mesylate—are approved for this patient population.
• No established algorithm exists for therapeutic sequencing.
• Median survival is measured in months, emphasizing the critical need for improved treatments.

Conclusions:

• Treatment selection for refractory MBC requires individualized assessment of patient performance status, toxicity, preferences, and quality of life.
• Further research is essential to enhance survival and quality of life for patients with advanced metastatic breast cancer.